Reviewing Bio-Techne Corporation (TECH)’s and AzurRx BioPharma Inc. (NASDAQ:AZRX)’s results

We are contrasting Bio-Techne Corporation (NASDAQ:TECH) and AzurRx BioPharma Inc. (NASDAQ:AZRX) on their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation. They both are Biotechnology companies, competing one another.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Bio-Techne Corporation 681.71M 11.16 96.31M 2.51 77.70
AzurRx BioPharma Inc. N/A 0.00 13.53M -0.88 0.00

Table 1 shows gross revenue, earnings per share and valuation of the two companies.


Table 2 shows us the net margins, return on equity and return on assets of both companies.

Net Margins Return on Equity Return on Assets
Bio-Techne Corporation 14.13% 8.9% 5.6%
AzurRx BioPharma Inc. 0.00% -301.4% -154.5%


The Current Ratio and Quick Ratio of Bio-Techne Corporation are 4.3 and 3.3 respectively. Its competitor AzurRx BioPharma Inc.’s Current Ratio is 3.9 and its Quick Ratio is 3.9. Bio-Techne Corporation can pay off short and long-term obligations better than AzurRx BioPharma Inc.


The annual dividend that Bio-Techne Corporation pay is $1.28 per share with a dividend yield of 0.63%. No dividend is paid out by AzurRx BioPharma Inc.

Analyst Recommendations

The next table highlights the given recommendations and ratings for Bio-Techne Corporation and AzurRx BioPharma Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Bio-Techne Corporation 0 2 2 2.50
AzurRx BioPharma Inc. 0 0 0 0.00

Bio-Techne Corporation’s downside potential currently stands at -6.45% and an $188.5 consensus price target.

Institutional and Insider Ownership

Institutional investors held 95.7% of Bio-Techne Corporation shares and 16.3% of AzurRx BioPharma Inc. shares. Insiders held 0.1% of Bio-Techne Corporation shares. Comparatively, 5.4% are AzurRx BioPharma Inc.’s share held by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Bio-Techne Corporation 0.1% 11.87% 19.62% 1.8% 38.59% 34.86%
AzurRx BioPharma Inc. -1.44% -2.97% 3.54% -18.65% -21.46% 69.42%

For the past year Bio-Techne Corporation has weaker performance than AzurRx BioPharma Inc.


On 11 of the 12 factors Bio-Techne Corporation beats AzurRx BioPharma Inc.

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates through three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers native and recombinant proteins, monoclonal and polyclonal antibodies, immunoassays, biologically active chemical compounds, and in situ genomic hybridization assays for the research and clinical diagnostics markets. It also provides various products, which serves as predictive biomarkers and therapeutic targets for various human diseases and conditions, including cancer, autoimmunity, diabetes, hypertension, obesity, inflammation, neurological disorders, and kidney failure. The Protein Platforms segment develops, manufactures, and sells tools, such as Biologics platform that enables researchers interrogate protein purity and identify contaminants during the development and production of biologics; Simple Western platform for protein analysis and identification; SimplePlex platform, an enzyme-linked immunosorbent assay for use in research and clinical diagnostics; and Single Cell Western platform to elucidate the properties of individual cells to understand cell behavior. The Diagnostics segment offers controls and calibrators for hematology clinical instruments; blood chemistry and blood gas quality controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market; bulk purified proteins, enzymes, disease-state plasmas, infectious disease antigens, and processed serums to the clinical diagnostic industry; and Paratest, a novel and convenient stool collection and test device for the veterinary market. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

AzurRx BioPharma, Inc., a clinical development stage biopharmaceutical company, engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, an autologous yeast recombinant lipase, which is in Phase IIa trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, a recombinant b-lactamase combination of bacterial origin for the prevention of hospital-acquired infections, as well as antibiotic-associated diarrhea. The company was incorporated in 2014 and is headquartered in Brooklyn, New York.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.